• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tufts CSDD Survey Finds Study Startup Cycles Remain Inefficient for New Sites

Tufts CSDD Survey Finds Study Startup Cycles Remain Inefficient for New Sites

January 29, 2018
Conor Hale

Companies reported 28 percent longer clinical trial cycle times and startup processes for new sites compared to repeat sites, according to a study conducted by the Tufts Center for the Study for Drug Development (Tufts CSDD) and goBalto.

Wide variation between companies showed that company practices have been highly inconsistent, according to the study, which focused on the end-to-end process from site identification to initiation. Start-up processes averaged five to six months, and only 10 percent of respondents said they were very satisfied with their study startup processes.

The report, based on the Start-up Time And Readiness Tracking (START) II study, found that contract research organizations described shorter total cycle times compared to sponsors — with CROs completing all site-related activities six to 11 weeks faster on average.

Meanwhile, the percentage of sites never activated held at 11 percent, and has not seen substantial changes in over a decade.

“Study startup through activation remains one of the most inefficient cycles facing clinical development operations,” said Ken Getz, associate professor at Tufts CSDD and the principal investigator of the START II study.

“The impetus behind this follow-up study was to gather hard data quantifying cycle time durations and clinical team experience to identify new insights into this perennial challenge,” said Getz. The study was published in Therapeutic Innovation & Regulatory Science, the official scientific journal of the DIA.

Investments in adequate clinical trials technology and data analytics largely led to time savings, with 30 percent of companies reporting shorter cycle times than companies with inadequate technologies, the report said.

“The results provided some very interesting insights about sponsor/CRO differences, centralized vs. decentralized site selection and start-up groups as well as the impact that technology has had on reducing cycle times,” said study co-author Beth Harper, president of Clinical Performance Partners.

“There’s more work to be done but our findings should help point organizations in the right direction to areas that will have the biggest impact,” Harper said.

The study surveyed biopharmaceutical companies and CROs, gathering data from 600 respondents and over 400 unique companies, approximately 65 percent from pharma and biotech, and 35 percent from CROs.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing